Please provide your email address to receive an email when new articles are posted on . In this video, Jakub Svoboda, MD, discusses a study presented at ASCO Annual Meeting that evaluated rituximab ...

Sergio A. Giralt, MD, discusses how rituximab plays a key role in treating chronic graft-vs-host disease. It is often used in combination with ibrutinib to enhance therapeutic outcomes. He reviews the ...

The authors made the rituximab fluorescent (FITC) and demonstrated that it binds to kidney sections (above) and to podocytes in culture (below). This is a major paradigm shift, as rituximab was ...

BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic ...

Patients were enrolled in the pre-transplant clinic. Blood collected prior to transplant was utilized at the bench to culture normal human podocytes in the presence or absence of rituximab and to ...